Aspergillus 5, 6-dihydropyran-2-one derivative 3-acetamido aspergillus pyranone A as well as preparation method and application of aspergillus 5, 6-dihydropyran-2-one derivative 3-acetamido aspergillus pyranone A
By extracting and purifying 3-acetamyl Aspergillus pyrone A from Aspergillus coronatus, the drug resistance problem of drug-resistant strains to antibiotics was solved, significantly inhibited the growth of a variety of pathogenic bacteria, and provided new antibacterials Drug precursors lay the material foundation for the development of antibacterial drugs.
Patent Information
- Application Number
- CN202411173497.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-26
AI Technical Summary
The therapeutic effect of existing antibiotics on drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) is reduced, resulting in severe clinical complications and death, and lack of effective antimicrobial precursor compounds.
Developed an Aspergillus 5,6-dihydropyran-2-one derivative 3-acetamido Aspergillus pyrone A, extracted from Aspergillus ceramide and passed silica gel column chromatography, macroporous resin column chromatography and high efficiency Purification by liquid chromatography, it has lipophilic fifteen-carbon long-chain olefin side chains, which are used to inhibit the growth of a variety of pathogenic bacteria.
3-acetamino Aspergillus pyrone A significantly inhibits the growth of Gram-positive and negative human pathogenic bacteria, including Staphylococcus aureus and E. coli, as well as the drug-resistant strain MRSA, providing effective drug precursors for antibacterial drugs. Development laid the foundation.
Smart Images

Figure CN119060006A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of natural medicines, and particularly relates to an Aspergillus 5,6-dihydropyran-2-one derivative 3-acetamido Aspergillus pyrone A, a preparation method and application thereof. Background Art
[0002] The discovery and application of antibiotics is an outstanding contribution to the history of human medicine. However, in recent years, with the widespread use of antibiotics worldwide, sensitive strains have gradually been eliminated, resistant strains have become the dominant bacterial population, and drug resistance can be transmitted between different species. The situation of drug-resistant bacterial infection is becoming more and more severe, and there is a serious shortage of clinically available antibiotics. Methicillin-resistant Staphylococcus aureus (MRSA) is a common and highly toxic bacterium in clinical practice. Since its discovery, MRSA has spread almost all over the world and has become one of the important pathogens of nosocomial and community infections. The therapeutic effect of conventional antibiotics on infections caused by drug-resistant MRSA has been greatly reduced, leading to serious clinical complications and death.
[0003] The strategies to contain bacterial resistance mainly focus on two aspects: one is to maintain the effectiveness of existing antimicrobial drugs, including infection prevention, rational drug use, combination therapy, improved dosage forms, etc.; the other is to promote the development of new antimicrobial drugs, including accelerating the development of suitable new drugs and vaccines. The structure and target of new antimicrobial drugs are different from those of traditional antibiotics, so they can play a better therapeutic effect on drug-resistant bacteria. The research and development of new antimicrobial drugs has shown considerable potential for the treatment of drug-resistant bacterial infections. Antibiotics derived from fungi, such as cephalosporins and penicillins, have significant antibacterial effects and low toxicity to humans. Studies have shown that compounds with lipophilic long side chains can act on the cell membrane of drug-resistant bacteria, thereby exerting good antibacterial activity (J Med Chem, 2015, 58, 739-752; J Med Chem, 2016, 59, 171-193). Therefore, it is an urgent problem for technicians in this field to accelerate the research of new antibacterial drugs, discover new structures of fungal-derived antibacterial substances, study their antibacterial effects on drug-resistant bacteria, and provide clinically with drug precursor compounds with rich structures and significant efficacy. Summary of the invention
[0004] In view of the deficiencies in the prior art, the present invention provides a 5,6-dihydropyran-2-one derivative 3-acetamidopyrone A and a preparation method thereof. The compound provides an effective drug precursor for the development of antibacterial drugs and also lays a material foundation for the next step of efficacy research.
[0005] To achieve the above object, the present invention provides the following technical solution: a 5,6-dihydropyran-2-one derivative of Aspergillus 3-acetamidopyrone A, characterized in that the structural formula of the compound is
[0006]
[0007] The compound was named 3-acetamido-5-hydroxy-6-[(7-vinyl-15-hydroxy)-pentadecyl]-5,6-dihydropyran-2-one.
[0008] The present invention also provides the use of the Aspergillus 5,6-dihydropyran-2-one derivative 3-acetamido Aspergillus pyrone A in inhibiting the growth of Gram-positive human pathogenic bacteria Staphylococcus aureus standard strains, Bacillus subtilis, and Bacillus subtilis, inhibiting the growth of Gram-negative human pathogenic bacteria Escherichia coli, inhibiting the growth of human pathogenic bacteria Staphylococcus aureus clinical strains, and inhibiting the human pathogenic drug-resistant strain methicillin-resistant Staphylococcus aureus MRSA.
[0009] In the third aspect of the present invention, a method for preparing the Aspergillus 5,6-dihydropyran-2-one derivative 3-acetamido Aspergillus pyrone A is provided, comprising the following steps:
[0010] (1) activating Aspergillus cristatus to form a seed liquid, and culturing and fermenting the seed liquid in a solid culture medium;
[0011] (2) extracting the fermented product obtained in step (1) by cold soaking with ethyl acetate, and concentrating under reduced pressure to obtain a crude extract;
[0012] (3) The crude extract in step (2) is purified by silica gel column chromatography, eluted by macroporous resin column chromatography, and then 3-acetamidoaspergillus pyrone A is separated and purified by high performance liquid chromatography.
[0013] Furthermore, the Aspergillus cristatus was streaked to revive, inoculated into PDA solid culture medium, and activated in a 28°C incubator for 5 days; a small piece of colony was cut from the PDA culture medium with a scalpel, inoculated into PDB liquid culture medium, and shaken and cultured on a shaker at 28°C and 120rpm for 5 days to obtain a seed solution.
[0014] Furthermore, the solid culture medium in step (1) is prepared by: 20-70 g of rice, 20-70 g of barley, and 70-150 mL of water, and then sterilized at 100-120° C. for 10-50 min after soaking overnight.
[0015] Furthermore, the seed solution was inoculated into a solid culture medium and statically cultured in a constant temperature and humidity chamber at 28° C. for 30 days.
[0016] Furthermore, in step (2), 400 mL of ethyl acetate is added for every 200 g of fermentation product.
[0017] Furthermore, in step (3), the silica gel column chromatography is used for impurity removal by eluting with petroleum ether-ethyl acetate (30:1 to 0:1).
[0018] Furthermore, in step (3), the elution gradient of the macroporous resin column chromatography is 10%, 30%, 50%, 70%, 90%, 100% methanol-water.
[0019] Furthermore, in step (3), 3-acetamidoaspergillus pyrone A is in a 90% methanol-10% water section.
[0020] Furthermore, the HPLC eluent in step (3) is methanol-acid water, mobile phase A is 60% to 100% methanol, mobile phase B is 40% to 0% acid water, the acid water is selected from one of the aqueous solutions of formic acid, acetic acid, phosphoric acid, and trifluoroacetic acid, the acid concentration is 0.01% to 1.0%, and the detection wavelength is 230nm.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The present invention proposes a novel structural type of Aspergillus 5,6-dihydropyran-2-one derivative, which has a lipophilic 15-carbon long-chain olefin side chain and may act on the bacterial cell membrane; the study found that 3-acetamido Aspergillus pyrone A can significantly inhibit the growth of three Gram-positive human pathogens, namely, standard strains of Staphylococcus aureus, Bacillus subtilis, and Bacillus thuringiensis, with MICs of 8.15±0.60μg / mL, 11.42±1.92μg / mL, and 24.9 3±2.51μg / mL; 3-acetamido aspergillus pyrone A can significantly inhibit the growth of Gram-negative human pathogenic bacteria Escherichia coli, with a MIC of 36.84μg / mL; 3-acetamido aspergillus pyrone A can significantly inhibit the growth of human pathogenic bacteria Staphylococcus aureus clinical strains, with a MIC of 12.82μg / mL; 3-acetamido aspergillus pyrone A has a significant antibacterial effect on human pathogenic resistant strains of methicillin-resistant Staphylococcus aureus MRSA, with a MIC of 23.61μg / mL. 3-acetamido aspergillus pyrone A can be used in the preparation of antibacterial drug precursors, laying a material foundation for the next step of biomedical development and application of antibacterial ingredients. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The colony morphology of Aspergillus cristatus is shown.
[0024] Figure 2 1H-1H COSY and key HMBC signals of 3-acetamidoaspergillus pyrone A are shown.
[0025] Figure 3 The 1H-NMR chart of 3-acetamidoaspergillus pyrone A is shown.
[0026] Figure 4 The 13C-NMR chart of 3-acetamidoaspergillus pyrone A is shown.
[0027] Figure 5 The 1H-1H COSY pattern of 3-acetamidoaspergillus pyrone A is shown.
[0028] Figure 6 The HSQC pattern of 3-acetamidoaspergillus pyrone A is shown.
[0029] Figure 7 The HMBC diagram of 3-acetamidoaspergillus pyrone A is shown.
[0030] Figure 8 The graph shows the antibacterial effect of 3-acetamidopyrone A on clinical strains of Staphylococcus aureus.
[0031] Fig. 9 The graph shows the antibacterial effect of 3-acetamido aspergillus pyrone A on MRSA. DETAILED DESCRIPTION
[0032] Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative work shall fall within the scope of protection of the present invention.
[0033] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] Example 1 Fermentation of strains and extraction of extract
[0035] Aspergillus cristatus was purchased from the American Standard Bacteria Collection (ATCC) with the accession number of ATCC 22166. The strain was revived by streaking, inoculated into PDA solid medium, and activated in a 28°C incubator for 5 days. A small piece of colony was cut from the PDA medium with a scalpel, inoculated into PDB liquid medium, and cultured on a shaker at 28°C and 120rpm for 5 days to obtain seed liquid. The seed liquid was then inoculated into a solid culture medium (40g of rice, 40g of barley, 125mL of water, and sterilized at 110°C for 25min after soaking overnight), and cultured in a 28°C constant temperature and humidity chamber for 30 days. Take the solid fermentation product, add 400mL of ethyl acetate for every 200g of fermentation product, cold soak and extract twice, and combine the extracts to reduce pressure and concentrate until there is no ethyl acetate taste to obtain ethyl acetate extract.
[0036] Example 2 Isolation and Identification of 3-Acetamido Aspergillus pyrone A
[0037] The extract was segmented by silica gel column chromatography and eluted with petroleum ether-ethyl acetate (30:1-0:1) respectively. After merging, it was divided into 8 sections (AH). The CG sections were combined and placed on an MCI column, adsorbed overnight, and eluted with 10%, 30%, 50%, 70%, 90%, and 100% methanol-water gradients. Each gradient eluted 5 column volumes. Each gradient was combined and dried until there was no liquid to obtain 6 subcomponents. The fifth subcomponent (90% methanol-water portion) was separated and purified by semi-preparative HPLC. The mobile phase was 85% methanol-water + 0.1% CF3COOH, the flow rate was 4.0 mL / min, the detection wavelength was 230 nm, and the peak time was 28.6-29.4 min. The peak was taken out and rotary evaporated to complete dryness to obtain 16.5 mg of white powder. The white powder was subjected to mass spectrometry and one-dimensional and two-dimensional nuclear magnetic resonance analysis. The results are as follows Figure 2-Figure 7 , the structure of the compound was determined to be The low-resolution mass spectrometry positive ion mode [M+Na]+m / z 418.3, [M+K]+m / z 434.3, negative ion mode [M+Cl]-m / z 430.4, from which it can be known that the molecular weight of the compound is 395, and the molecular formula of the compound is C22H37NO5. Its 1H and 13C NMR data are shown in Table 1. From the 1H and 13C NMR data, it can be seen that the compound has 2 carbonyl groups (C-2 and C-22), 4 olefinic carbons (C-3, C-4, C-7, C-8), 3 oxygen-linked quaternary carbons (C-5, C-6, C-15), 11 methylene groups (C-9, C-10, C-11, C-12, C-13, C-14, C-16, C-17, C-18, C-19, C-20), and 2 methyl groups (C-21, C-23). The signals were assigned by combining 2D NMR data such as 1H-1H COSY (homonuclear correlation spectrum), HSQC (heteronuclear single quantum correlation) and HMBC (multi-bond carbon-hydrogen relationship spectrum). The pyrone ring was confirmed by 1H-1H COSY signals from H-4 / H-5 / H-6, and HMBC signals from H-4 to C-2 / C-3 / C-5 / C-6, H-5 to C-3 / C-4 / C-6, and H-6 to C-5. The 3-acetamido substitution was confirmed by key HMBC signals from amide hydrogen to C-2 / C-4 / C-22 and H3-23 to C-22. The 15-carbon long side chain at position 6 was confirmed by the 1H-1H COSY signals of H-7 / H-8 / H-9 / H-10, H-10 / H-11 / H-12, H-13 / H-14 / H-15 / H-16 / H-17, H-17 / H-18 / H-19 / H-20 / H-21, and the key HMBC signals of H-7 to C-8 / C-9, H-8 to C-9 / C-10, H-15 to C-13 / C-14 / C-16 / C-17, H3-21 to C-19 / C-20. The 15-carbon long side chain substitution at position C-6 was confirmed by the key HMBC signals H-6 to C-7 / C-8, H-7 to C-5 / C-6, H-8 to C-6. The structure of the compound was thus determined. The novel structural compound proposed in the present invention is a 5,6-dihydropyran-2-one derivative, wherein the 3-position is substituted by an acetamido group and the 6-position is substituted by a 15-carbon long-chain olefin. The structure of the novel structural compound is 3-acetamido-5-hydroxy-6-[(7-vinyl-15-hydroxy)-pentadecanyl]-5,6-dihydropyran-2-one, and the common name thereof is 3-acetamido aspergillus pyrone A.
[0038] Table 1 Compounds 1 H(500MHz) and 13 C(125MHz) NMR data(CDCl3)
[0039]
[0040]
[0041] Test Example 1 Inhibition experiment on three common strains of Gram-positive human pathogenic bacteria
[0042] The human pathogenic bacteria used in the antibacterial experiment were Staphylococcus aureus ATCC25922, Bacillus subtilis ATCC 6633, and Bacillus altitudinis. The bacteria were activated on beef extract peptone medium plates at 37°C for 24 hours, colonies were picked and added to MH culture medium (Mueller-Hinton Broth), shaken and cultured for 6 hours, and the bacterial solution was diluted to 1.0×104~1.0×105CFU / mL. 3-acetamido aspergillus pyrone A was dissolved in DMSO and diluted with MH culture medium to 200.0, 100.0, 50.0, 25.0, and 12.5μg / mL of the test solution. The blank group was added with 200 μL MH culture medium, the positive group was added with 100 μL positive drug penicillin G sodium solution and 100 μL bacterial suspension, the test group was added with 100 μL test sample 3-acetamido aspergillus pyrone A solution and 100 μL bacterial suspension, and the growth group was added with 100 μL MH culture medium and 100 μL bacterial suspension. After culturing for 24 hours at 37 ° C, the OD value at 530 nm was measured by a microplate reader, and 3 parallels were set for each group. The MIC (minimum inhibitory concentration) value is the drug concentration at which the OD value of the bacterial solution drops by half. The GraphPad Prism 8 software was used for statistical analysis and calculation of the MIC value and ± SD (standard deviation) value. The results showed that 3-acetamido aspergillus pyrone A had a significant antibacterial effect on three strains of human pathogenic Gram-positive bacteria, with a MIC of 8.15-24.93 μg / mL. Studies have shown that 3-acetamidoaspergillus pyrone A has a lipophilic 15-carbon long side chain. This type of compound can destroy the bacterial cell membrane and thus exert an antibacterial effect.
[0043] Table 2 MICs of 3-acetamidopyrone A against three Gram-positive human pathogens (μg / mL)
[0044]
[0045] Test Example 2: Antibacterial effect on a Gram-negative human pathogen
[0046] The strain Escherichia coli (E.coli ATCC 25922) used was activated on a beef extract peptone medium plate at 37°C for 24h, and the colonies were picked and added to MH culture medium, shaken and cultured for 6h, and the bacterial solution was diluted for use. 3-acetamido aspergillus pyrone A was dissolved in DMSO and diluted with MH culture medium to 200.0, 100.0, 50.0, 25.0, and 12.5μg / mL of the test solution. The test group added 100μL of different concentrations of 3-acetamido aspergillus pyrone A solution and 100μL of bacterial suspension, and the positive group added 100μL of positive drug streptomycin sulfate and 100μL of bacterial suspension. After culturing at 37°C for 24h, the OD value at 530nm was measured with an enzyme marker, and 3 parallels were set for each group. The results showed that 3-acetamido aspergillus pyrone A had a significant inhibition rate on Escherichia coli, and the MIC was 36.84μg / mL. The MIC value of streptomycin sulfate against this strain of Escherichia coli was 1.08 μg / mL.
[0047] Test Example 3 Antibacterial Effect on Clinical Strain of Staphylococcus aureus Pathogenic to Human Body
[0048] The clinical strain of Staphylococcus aureus (S.aureus clinical isolate) was activated on a beef extract peptone medium plate at 37°C for 24 hours, and the colonies were picked and added to MH culture medium. The culture was shaken for 6 hours, and the bacterial solution was diluted for later use. 3-Acetamidoaspergillus pyrone A was dissolved in DMSO and diluted with MH culture medium to 200.0, 100.0, 50.0, 25.0, and 12.5 μg / mL of the test solution. The test group was added with 100 μL of 3-acetamidoaspergillus pyrone A solution of different concentrations and 100 μL of bacterial suspension, with tigecycline as the positive drug. After culturing at 37°C for 24 hours, the OD value at 530 nm was measured with an enzyme reader, and 3 parallels were set up for each group. The results showed that ( Figure 8 ), the inhibition rate of 12.5μg / mL 3-acetamido aspergillus pyrone A against the clinical strain of Staphylococcus aureus was 47.7%, and the inhibition rate of 25.0μg / mL 3-acetamido aspergillus pyrone A against the clinical strain of Staphylococcus aureus was 77.6%. The MIC of 3-acetamido aspergillus pyrone A against the clinical strain of Staphylococcus aureus was calculated to be 12.82μg / mL. The MIC value of the positive drug tigecycline against the clinical strain of Staphylococcus aureus was 1.25μg / mL, and the MIC value of penicillin G sodium against the clinical strain of Staphylococcus aureus was 60.53μg / mL. The strain had strong resistance to penicillin G sodium. 3-acetamido aspergillus pyrone A had a significant antibacterial effect on the clinical strain of Staphylococcus aureus that causes human pathogens.
[0049] Test Example 4: Antibacterial effect on human pathogenic drug-resistant strain MRSA
[0050] Methicillin-resistant Staphylococcus aureus (MRSA) was activated on beef extract peptone medium plates at 37°C for 24 hours, colonies were picked and added to MH culture medium, shaken and cultured for 6 hours, and the bacterial solution was diluted for later use. 3-Acetamidoaspergillus pyrone A was dissolved in DMSO and diluted with MH culture medium to 200.0, 100.0, 50.0, 25.0, and 12.5 μg / mL of the test solution, with tigecycline as the positive drug. 100 μL of compound solutions of different concentrations and 100 μL of bacterial suspension were added to the test group. After culturing at 37°C for 24 hours, the OD value at 530 nm was measured with an enzyme reader, and 3 parallels were set up for each group. The results showed that ( Fig. 9 ), the inhibition rate of 50.0μg / mL 3-acetamido aspergillus pyrone A to MRSA was 82.2%, and the inhibition rate of 25.0μg / mL 3-acetamido aspergillus pyrone A to MRSA was 46.8%. The MIC of 3-acetamido aspergillus pyrone A to MRSA was calculated to be 23.61μg / mL. The MIC value of the positive drug tigecycline to this strain of MRSA was 6.25μg / mL, and the MIC value of penicillin G sodium to this clinical strain of Staphylococcus aureus was greater than 100μg / mL. The MRSA strain was completely resistant to penicillin G sodium. 3-acetamido aspergillus pyrone A has a significant antibacterial effect on human pathogenic resistant MRSA.
[0051] In summary, the present invention proposes a novel structure of Aspergillus pyrone 3-acetamido Aspergillus pyrone A, in which the 2-position of Aspergillus pyrone is substituted by an acetamido group and the 5-position is substituted by a 15-carbon long-chain olefin. The study found that 3-acetamido Aspergillus pyrone A can significantly inhibit the growth of three Gram-positive human pathogenic bacteria, namely, the standard strain of Staphylococcus aureus, Bacillus subtilis, and Bacillus aureus, with MICs of 8.15±0.60μg / mL, 11.42±1.92μg / mL, and 24.9 3±2.51μg / mL; 3-acetamido aspergillus pyrone A can significantly inhibit the growth of Gram-negative human pathogenic bacteria Escherichia coli, with a MIC of 36.84μg / mL; 3-acetamido aspergillus pyrone A can significantly inhibit the growth of human pathogenic bacteria Staphylococcus aureus clinical strains, with a MIC of 12.82μg / mL; 3-acetamido aspergillus pyrone A has a significant antibacterial effect on human pathogenic resistant strains of methicillin-resistant Staphylococcus aureus MRSA, with a MIC of 23.61μg / mL. 3-acetamido aspergillus pyrone A can be used in the preparation of antibacterial drug precursors, laying a material foundation for the next step of biomedical development and application of antibacterial ingredients.
[0052] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0053] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A 5,6-dihydropyran-2-one derivative of Aspergillus 3-acetamidopyrone A, characterized in that: The structural formula of the compound is The compound was named 3-acetamido-5-hydroxy-6-[(7-vinyl-15-hydroxy)-pentadecyl]-5,6-dihydropyran-2-one.
2. The Aspergillus 5,6-dihydropyran-2-one derivative 3-acetamido Aspergillus pyrone A according to claim 1 is used to inhibit the growth of Gram-positive human pathogenic bacteria Staphylococcus aureus standard strains, Bacillus subtilis, and Bacillus subtilis, inhibit the growth of Gram-negative human pathogenic bacteria Escherichia coli, inhibit the growth of human pathogenic bacteria Staphylococcus aureus clinical strains, and inhibit the growth of human pathogenic drug-resistant strains of methicillin-resistant Staphylococcus aureus MRSA.
3. The method for preparing 3-acetamido aspergillus pyrone A of Aspergillus 5,6-dihydropyran-2-one derivative according to claim 1, characterized in that: The following steps are involved: (1) activating Aspergillus cristatus to form a seed liquid, and culturing and fermenting the seed liquid in a solid culture medium; (2) extracting the fermented product obtained in step (1) by cold soaking with ethyl acetate, and concentrating under reduced pressure to obtain a crude extract; (3) The crude extract in step (2) is purified by silica gel column chromatography, eluted by macroporous resin column chromatography, and then 3-acetamidoaspergillus pyrone A is separated and purified by high performance liquid chromatography.
4. The method for preparing 3-acetamido aspergillus pyrone A of Aspergillus 5,6-dihydropyran-2-one derivative according to claim 3, characterized in that: The Aspergillus cristatus was streaked to revive, inoculated into PDA solid culture medium, and activated in a 28°C incubator for 5 days; a small piece of colony was cut from the PDA culture medium with a scalpel, inoculated into PDB liquid culture medium, and shaken and cultured on a shaker at 28°C and 120 rpm for 5 days to obtain a seed solution.
5. The method for preparing 3-acetamido aspergillus pyrone A of Aspergillus 5,6-dihydropyran-2-one derivative according to claim 3, characterized in that: The solid culture medium in step (1) is prepared by: 20-70 g of rice, 20-70 g of barley, and 70-150 mL of water, and then sterilized at 100-120° C. for 10-50 min after soaking overnight.
6. The method for preparing 3-acetamido aspergillus pyrone A, a derivative of Aspergillus 5,6-dihydropyran-2-one, according to claim 3, characterized in that: The seed solution was inoculated into the solid culture medium and cultured statically in a constant temperature and humidity chamber at 28°C for 30 days.
7. The method for preparing 3-acetamido aspergillus pyrone A, a derivative of Aspergillus 5,6-dihydropyran-2-one, according to claim 3, characterized in that: In step (2), 400 mL of ethyl acetate was added for every 200 g of fermentation product.
8. The method for preparing 3-acetamido aspergillus pyrone A, a derivative of Aspergillus 5,6-dihydropyran-2-one, according to claim 3, characterized in that: In step (3), the silica gel column chromatography is used for impurity removal by eluting with petroleum ether-ethyl acetate (30:1 to 0:1).
9. The method for preparing 3-acetamido aspergillus pyrone A, a derivative of Aspergillus 5,6-dihydropyran-2-one, according to claim 3, characterized in that: The elution gradient of the macroporous resin column chromatography in step (3) is 10%, 30%, 50%, 70%, 90%, and 100% methanol-water.
10. The method for preparing 3-acetamido aspergillus pyrone A, a derivative of Aspergillus 5,6-dihydropyran-2-one, according to claim 3, characterized in that: In step (3), 3-acetamido aspergillus pyrone A is a 90% methanol-10% water section.
11. The method for preparing 3-acetamido aspergillus pyrone A, a derivative of Aspergillus 5,6-dihydropyran-2-one, according to claim 3, characterized in that: The HPLC eluent in step (3) is methanol-acid water, mobile phase A is 60% to 100% methanol, mobile phase B is 40% to 0% acid water, the acid water is selected from one of aqueous solutions of formic acid, acetic acid, phosphoric acid, and trifluoroacetic acid, the acid concentration is 0.01% to 1.0%, and the detection wavelength is 230nm.
Citation Information
Patent Citations
Dihydro-pyranone compound and preparation method and medical application thereof
CN103044375A
3,4,6-Trisubstituted-alpha-pyrone derivative and preparation method and application thereof
CN107954964A
Macrolide compound aspergillus lactone A
CN115197192A
Preparation method and application of aspergillus butene lactone derivative
CN118239913A
